# The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart Failure

> **NCT02129179** · PHASE1 · COMPLETED · sponsor: **Papworth Hospital NHS Foundation Trust** · enrollment: 10 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Glucagon-Like Peptide 1

## Key facts

- **NCT ID:** NCT02129179
- **Lead sponsor:** Papworth Hospital NHS Foundation Trust
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2018-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02129179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02129179, "The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart Failure". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02129179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*